The European Journal of Neuroscience, NECTAR and the Cure Parkinson’s Trust have published an EJN Special Issue dedicated to Tom Isaacs. For more information, please visit the CPT website. Here are our summaries of some of the articles that have been published in the issue:
In memory of Tom Isaacs
The epitomical mover and shaker of the Parkinson’s world
Nasal delivery of exenatide
Targeting cells in the olfactory bulb using antidiabetic drug.
AUDIO VERSION AVAILABLE.
Biomaterials and neuron survival
GDNF-loaded collagen scaffold increased survival of cells.
AUDIO VERSION AVAILABLE.
The immune system in Parkinson’s
Innate and the adaptive immune system responses
Power of the Parkinson’s patient
A call to action within the Parkinson’s community to work together
Mitochondria and inflammation
Insights into pathways in mitochondria and oxidative stress
Cell replacement therapies short history
Paralleling to the framework of the Star Wars storyline
Understanding Levodopa
Long term Levodopa-induced dyskinesias in Parkinson’s
Animal models of Parkinson’s
Call for complete characterisation of new models
Exosomes as new biomarker
Changes in messenger proteins released by neurons detected
CRISPR gene editing method
Researchers are using gene editing to remove alpha-synuclein.
AUDIO VERSION AVAILABLE
HIF1a: Growing better stem cells
Promising strategy improving dopamine neuron growth in the lab
International Linked Clinical Trials
Drugs with the potential of stopping, slowing or reversing Parkinson’s
Biomaterials in cell replacement
Using biological materials to support cell transplantation
Levodopa-induced dyskinesia drugs
Developing novel drugs that target multiple receptors
Subtypes of Parkinson’s
Identifying subtypes to help tailor treatments and clinical trials
Neurotrophic factors in Parkinson’s
The clinical history and future of regenerative therapies
Who might exenatide benefit?
Analysing which factors may predict a positive response
LRRK2 and alpha synuclein interaction
Wide range of evidence supporting potential interactions
Targeting alpha synuclein to improve constipation
A phase II open label trial of a novel drug targeting
Capitalising on the neuroprotective effects of a prostate drug
A prostrate drug (Terazosin) has been shown to exert neuroprotective effects in animal models.
AUDIO VERSION AVAILABLE.
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease
Regular home-based aerobic exercise appears to reduce the progression of Parkinson’s.
AUDIO VERSION AVAILABLE.
Where gender matters: understanding the results of the SURE-PD trial
The SURE-PD trial has indicated inosine was effective at increasing urate levels and slowing disease progression in women, but not men.
AUDIO VERSION AVAILABLE.
Focused ultrasound – a new way of enhancing drug delivery?
Focus ultrasound (FUS) is a promising new area to improve delivery of drugs and neurotrophic factors
Cysteamine: another potential candidate on the horizon?
Evidence from preclinical studies supports case for a clinical trial of cysteamine in PwP
Promising results with anle138b, a new drug that prevents protein clumping
anle138b shown to prevent clumping of alpha synuclein
Gene therapy with GDNF: the results of the US trial
Gene therapy with GDNF: results of US trial.
AUDIO VERSION AVAILABLE
Study investigates NAC – but what about the placebo effect?
Study without blinding or a placebo arm has shown benefits from NAC.
Hypertension drug enhances autophagy
Felodipine drug seen to improve neuronal survival
